[Survivin在胶质瘤中的核表达及其与预后的相关性]

Pan Yi, Hu Wei-Han, Xie Dan, Wu Hui-Xi, Xiang Jin, Liu Yong-Dong, Wu Qiu-Liang, Liu Yan-Hui

State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, P. R. China.

Ai Zheng. 2006 May;25(5):635-9.

BACKGROUND & OBJECTIVE: Survivin, an inhibitor of apoptosis protein, is correlated to aggressive behavior, resistance to chemotherapy and radiotherapy, and prognosis of human cancers. It is expressed in both nuclei and cytoplasm. Recent research revealed that the nuclear expression of survivin is an important prognostic factor of human cancers. This study was to investigate the nuclear expression of Survivin in human glioma, and its correlations to clinicopathologic characteristics and prognosis.

METHODS

The nuclear expression of Survivin in 88 specimens of glioma (33 at grade I-II, and 55 at grade III-IV) was detected by tissue microarray and immunohistochemistry. Its correlations to clinicopathologic characteristics and prognosis were analyzed.

RESULTS

The positive rate of nuclear Survivin was 27.3% in the whole group. It was significantly lower in grade I-II gliomas than in grade III-IV gliomas (12.1% vs. 36.4%, P=0.013). Nuclear expression of Survivin had no correlation to patient's age (P=0.053), sex (P=0.376), Karnofsky performance status (P=0.486), and clinical stage (P=0.359). The 5-year overall survival rate and 3-year disease-freely survival rate were significantly lower in nuclear Survivin-positive group than in nuclear Survivin-negative group (22.7% vs. 47.7%, P=0.005; 13.7% vs. 39.5%, P=0.015). The median survival was slightly lower in high nuclear Survivin expression group than in low nuclear Survivin expression group (14.9 months vs. 20.2 months, P=0.089).

CONCLUSIONS

The nuclear expression of Survivin is related to the pathologic grade of glioma, and might be a negative prognostic factor of glioma.

背景与目的

生存素作为一种凋亡抑制蛋白，与人类癌症的侵袭性、化疗和放疗抵抗以及预后相关。它在细胞核和细胞质中均有表达。近期研究表明，生存素的核表达是人类癌症的一个重要预后因素。本研究旨在探讨生存素在人类胶质瘤中的核表达及其与临床病理特征和预后的关系。

方法

采用组织芯片和免疫组化法检测88例胶质瘤标本（I-II级33例，III-IV级55例）中生存素的核表达。分析其与临床病理特征和预后的关系。

结果

全组核生存素阳性率为27.3%。I-II级胶质瘤中的阳性率显著低于III-IV级胶质瘤（12.1%对36.4%，P=0.013）。生存素的核表达与患者年龄（P=0.053）、性别（P=0.376）、卡氏功能状态（P=0.486）及临床分期（P=0.359）均无相关性。核生存素阳性组的5年总生存率和3年无病生存率显著低于核生存素阴性组（22.7%对47.7%，P=0.005；13.7%对39.5%，P=0.015）。高核生存素表达组的中位生存期略低于低核生存素表达组（14.9个月对20.2个月，P=0.089）。